Published in Clin Dev Immunol on November 22, 2004
Differential angiogenic regulation of experimental colitis. Am J Pathol (2006) 1.55
Protein expression analysis of inflammation-related colon carcinogenesis. J Carcinog (2009) 0.98
Patterns of airway involvement in inflammatory bowel diseases. World J Gastrointest Pathophysiol (2014) 0.96
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Ther Clin Risk Manag (2007) 0.87
Genetic deletion of Klf4 in the mouse intestinal epithelium ameliorates dextran sodium sulfate-induced colitis by modulating the NF-κB pathway inflammatory response. Inflamm Bowel Dis (2014) 0.86
Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells. Endocrinology (2008) 0.86
Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis. Immunology (2005) 0.85
Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med (2010) 0.85
Bugging inflammation: role of the gut microbiota. Clin Transl Immunology (2016) 0.84
Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm Res (2010) 0.82
Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis (2014) 0.81
B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease. Dig Dis Sci (2016) 0.81
Alopecia areata, primary sclerosing cholangitis, and ulcerative colitis: autoimmunity and apoptosis as common links? Dig Dis Sci (2007) 0.81
Ulcerative colitis: a challenge to surgeons. Int J Prev Med (2012) 0.80
Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int J Mol Sci (2010) 0.78
Inflammatory bowel diseases: when natural friends turn into enemies-the importance of CpG motifs of bacterial DNA in intestinal homeostasis and chronic intestinal inflammation. Int J Inflam (2010) 0.77
Autoantibodies and an immune-based rat model of inflammatory bowel disease. World J Gastroenterol (2013) 0.77
Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis. Dig Dis Sci (2009) 0.77
Inhibition of Pim-1 kinase ameliorates dextran sodium sulfate-induced colitis in mice. Dig Dis Sci (2012) 0.77
Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (N Y) (2007) 0.76
Bioactivity of Polyphenols: Preventive and Adjuvant Strategies toward Reducing Inflammatory Bowel Diseases-Promises, Perspectives, and Pitfalls. Oxid Med Cell Longev (2016) 0.75
Investigation of sesamol on myeloperoxidase and colon morphology in acetic acid-induced inflammatory bowel disorder in albino rats. ScientificWorldJournal (2014) 0.75
Coombs negative autoimmune hemolytic anemia in Crohn's disease. Am J Case Rep (2014) 0.75
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therap Adv Gastroenterol (2016) 0.75
Ulcerative colitis. N Engl J Med (2011) 6.14
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology (2003) 2.53
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol (2006) 1.79
Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol (2007) 1.64
Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev (2004) 1.61
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol (2009) 1.51
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol (2004) 1.51
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology (2006) 1.41
Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis (2007) 1.30
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 1.27
Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis. J Pharmacol Exp Ther (2004) 1.27
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol (2006) 1.23
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol (2004) 1.17
Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.17
Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis (2010) 1.12
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol (2005) 1.04
Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2011) 1.03
An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol (2005) 1.03
Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci (2008) 1.02
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety? N Engl J Med (2004) 1.02
Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology (2010) 0.97
Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis (2002) 0.97
Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis (2008) 0.96
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold. J Immunol (2005) 0.95
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.95
Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest (2002) 0.93
Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther (2006) 0.93
HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology (2002) 0.92
Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol (2008) 0.91
Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis (2014) 0.91
Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology (2005) 0.90
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology (2006) 0.90
Pathogenesis of postoperative recurrence in Crohn's disease. Gut (2010) 0.90
In vitro model of acute esophagitis in the cat. Am J Physiol Gastrointest Liver Physiol (2005) 0.89
Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol (2003) 0.89
HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol (2010) 0.88
Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol (2005) 0.88
Inflammatory bowel disease. Best Pract Res Clin Gastroenterol (2002) 0.87
Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86
Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis (2013) 0.85
Intestinal fibroblast-derived IL-10 increases survival of mucosal T cells by inhibiting growth factor deprivation- and Fas-mediated apoptosis. J Immunol (2005) 0.85
Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm Bowel Dis (2003) 0.85
Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets (2008) 0.84
Progress in basic inflammatory bowel disease research. Semin Pediatr Surg (2007) 0.82
Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am J Gastroenterol (2009) 0.81
Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology (2012) 0.81
News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010. J Crohns Colitis (2010) 0.80
Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J Immunol (2004) 0.80
Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized? Dig Dis (2015) 0.79
Inflammatory bowel disease: evolutionary concepts in biology, epidemiology, mechanisms and therapy. Curr Opin Gastroenterol (2013) 0.79
The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol (2009) 0.79
Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet (2013) 0.79
Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.79
Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol (2005) 0.78
A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease. Inflamm Bowel Dis (2013) 0.78
Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology (2012) 0.78
IBD: advances in pathogenesis, complications, diagnosis, and therapy. Curr Opin Gastroenterol (2012) 0.78
Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients. Am J Physiol Gastrointest Liver Physiol (2004) 0.77
Early and late inflammatory bowel disease: why and how are they different? Curr Opin Gastroenterol (2011) 0.77
Probiotics in inflammatory bowel disease: yet another mechanism of action? Gastroenterology (2006) 0.77
Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation (2003) 0.76
Targeting the innate immune system in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol (2011) 0.76
Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis (2007) 0.76
Inflammatory bowel disease: new insights into mechanisms of inflammation and increasingly customized approaches to diagnosis and therapy. Curr Opin Gastroenterol (2004) 0.76
Eosinophilic esophagitis: new insights into an emerging disease. Gastroenterology (2006) 0.75
Current perspectives in inflammatory bowel disease: stress response and autophagy, host-microbe mutualism, immune duality and plasticity, and early versus late disease. Curr Opin Gastroenterol (2010) 0.75
More answers and more questions in inflammatory bowel disease. Curr Opin Gastroenterol (2003) 0.75
Inflammatory bowel disease: genetics and much more. Curr Opin Gastroenterol (2002) 0.75
First international summit on fibrosis in intestinal inflammation: mechanisms and biological therapies. Fibrogenesis Tissue Repair (2010) 0.75
Endothelial Cell-Immune Cell Interaction in IBD. Dig Dis (2016) 0.75
Non-stop progress in inflammatory bowel disease: new players, new understanding, new therapies. Curr Opin Gastroenterol (2006) 0.75